What are the treatment options for MDS

Q: What are the treatment options for MDS

According to the NCCN Guidelines for Myelodysplastic Syndromes, treatment depends on your risk level and specific situation. Supportive Care: - Blood transfusions for anemia - Growth factors to boost blood counts - Iron, folate, or B12 replacement if needed For Anemia Specifically: - Lenalidomide if you have del5q deletion - Imetelstat preferred option for ring sideroblasts with SF3B1 mutation - Luspatercept-aamt for certain anemia patterns - Erythropoiesis-stimulating agents ESAs like epoetin a

MDSSeptember 25, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case. No signup, answered right here.

or Upload your records for answers about your actual case

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

Grounded in NCCN Guidelines for Patients: Myelodysplastic Syndromes — the same guidelines oncologists use.
Developed under the medical oversight of OpenCancer’s physician-scientist team (Chris Apfel, MD/PhD/MBA, CMO · Kaumudi Bhawe, PhD, CSO).
Last updated September 25, 2026. Informational only — not a substitute for your oncology team.

Treatment Options for MDS

According to the NCCN Guidelines for Myelodysplastic Syndromes, treatment depends on your risk level and specific situation.

Lower-Risk MDS (Very-Low, Low, or Intermediate-Risk)

Supportive Care:

Blood transfusions for anemia
Growth factors to boost blood counts
Iron, folate, or B12 replacement if needed

For Anemia Specifically:

Lenalidomide (if you have del(5q) deletion)
Imetelstat (preferred option for ring sideroblasts with SF3B1 mutation)
Luspatercept-aamt (for certain anemia patterns)
Erythropoiesis-stimulating agents (ESAs) like epoetin alfa or darbepoetin alfa
G-CSF (growth factor)

Other Options:

Immunosuppressive therapy (IST) with ATG or cyclosporin A for select patients
Eltrombopag for severe low platelet counts

Higher-Risk MDS

Hypomethylating agents: Azacitidine or Decitabine (these slow cancer cell growth)
IDH inhibitors: Ivosidenib (if IDH1 mutation) or Enasidenib (if IDH2 mutation)
Stem cell transplant (for eligible patients)
Clinical trials

If Disease Progresses or Doesn't Respond

Your doctor may switch to higher-risk treatment strategies or consider stem cell transplant.

Your oncologist will determine which approach fits YOUR specific situation based on your blood counts, mutations, and overall health.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation. No signup, answered right here.

or Upload your records for answers about your actual case

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →